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Abstract
Background: Although obstructive sleep apnea (OSA) is more common in patients with kidney disease, whether nocturnal
hypoxia affects kidney function is unknown.
Methods: We studied all adult subjects referred for diagnostic testing of sleep apnea between July 2005 and December 31
2007 who had serial measurement of their kidney function. Nocturnal hypoxia was defined as oxygen saturation (SaO2)
below 90% for $12% of the nocturnal monitoring time. The primary outcome, accelerated loss of kidney function, was
defined as a decline in estimated glomerular filtration rate (eGFR) $4 ml/min/1.73 m
2 per year.
Results: 858 participants were included and followed for a mean study period of 2.1 years. Overall 374 (44%) had nocturnal
hypoxia, and 49 (5.7%) had accelerated loss of kidney function. Compared to controls without hypoxia, patients with
nocturnal hypoxia had a significant increase in the adjusted risk of accelerated kidney function loss (odds ratio (OR) 2.89,
95% confidence interval [CI] 1.25, 6.67).
Conclusion: Nocturnal hypoxiawasindependently associated withanincreasedriskofacceleratedkidney functionloss. Further
studies are required to determine whether treatment and correction of nocturnal hypoxia reduces loss of kidney function.
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Introduction
Chronic hypoxia and tubulointerstitial injury are common to all
forms of kidney disease [1]. This has led to the ‘‘chronic hypoxia
hypothesis’’ first proposed by Fine et al. [2] which emphasizes
chronic ischemic damage in the tubulointerstitium as a final
common pathway in end-stage kidney injury. Support for an
association between hypoxia and development of progressive
chronic kidney disease comes from numerous in-vitro and in-vivo
studies of the effect of hypoxia on tubular and interstitial cells [3],
while human physiology studies also demonstrate alterations in
renal hemodynamics directly attributable to hypoxia [4,5].
Although the Sleep Heart Health Study suggested an association
between nocturnal hypoxia and risk of hypertension [6], reports
on the effect of sleep disordered breathing on renal function are
not consistent [7,8,9,10,11,12,13] and there are no studies
examining loss of kidney function as the primary outcome.
Sleep diagnostic testing provides a unique opportunity to
evaluate whether obstructive sleep apnea (OSA) and accompany-
ing hypoxia are associated with accelerated loss of kidney function
as patients undergo comprehensive assessment of their nocturnal
oxygen saturation profile. The increasingly high prevalence of
sleep-disordered breathing in the general community [14] coupled
with the potential for nocturnal hypoxia to cause deterioration
in kidney function [1,2,3] prompted our investigation of the
relationship between nocturnal hypoxia and loss of kidney
function in a cohort referred for evaluation of sleep apnea.
Methods
Objectives
The primary outcome was accelerated loss of kidney function,
defined as a decrease in eGFR $4 mL/min/1.73 m
2/year, which
is more than double the anticipated normal rate of decline [15,16].
The secondary outcome was the rate of loss of kidney function in
mL/min/1.73 m
2 per year.
Participants
A cohort of all patients aged $18 years referred between July
2005 and December 2007 for diagnostic testing of sleep apnea to
the Foothills Medical Centre (FMC) Sleep Centre or community
respiratory care companies within the Calgary Health Region
(population ,1.3 million) were identified. Patients who had a
previous diagnosis of sleep apnea or who had prior diagnostic
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toring) were excluded.
Description of Procedures or Investigations undertaken
Using the unique provincial health care number for each subject,
this cohort of patients with diagnostic sleep testing was linked to the
Alberta Kidney Disease network repository of laboratory data to
determine out-patient serum creatinine measurements [17]. Given
that sleep apnea is a chronic condition [18], we included outpatient
creatinine measurements in the one year period prior to the sleep
study for assessment of baseline kidney function. To be eligible for
inclusion, participants required 2 or more outpatient creatinine
measurements during the study period (i.e. from 1 year prior to
their sleep test to the end of follow-up (December 31, 2007)) to
enable assessment of serial kidney function. The first serum
creatinine result in the study period was used to define baseline
kidney function and subsequent measurements were used to
determine rate of change in kidney function. Subjects were
censored at death or study end. While all available serum creatinine
measurements within the study period were used to derive the rate
of loss, serum creatinine measurements associated with a hospital
admission were excluded to reduce the risk that episodes of acute
kidney injury would be classified as accelerated loss of kidney
function [16]. Patients were also excluded if they were receiving
renal replacement therapy (hemodialysis, peritoneal dialysis, or
kidney transplant) at study enrolment [19].
Measurement of Kidney Function and Definition of
Outcomes
Estimated glomerular filtration rate (eGFR) was used to estimate
kidney function using the abbreviated Modification of Diet in Renal
Disease (MDRD) equation [20]. Although data for race were not
available, misclassification of eGFR was expected to be minimal
because less than 2% of the Alberta population is black [21]. Given
concerns about the validity of the MDRD equation for subjects with
higher levels of kidney function [22], patients with baseline eGFR
values exceeding 90 mL/min/1.73 m
2 were excluded.
Study Variables and their Measurement
Sleep and Oxygenation Assessment. All subjects underwent
attended polysomnography (PSG) in the sleep laboratory at Foothills
Medical Centre or unattended nocturnal cardio-pulmonary moni-
toring at home (Remmers Sleep Recorder, SagaTech Electronics
Inc., Calgary, Canada). PSG data were recorded by a computerized
polysomnographic system (Sandman Elite Version 8.0, Nellcor
Puritan Bennett (Melville) Ltd, Kanata, Ontario, Canada). This
included a standardized montage: three channel electroencephalo-
grams (C4/A1, C3/A2, O1/A2), bilateral electro-oculograms
(EOG), submental electromyogram (EMG), bilateral leg EMGs,
and electrocardiography (ECG). Airflow was measured using a nasal
pressure transducer (Braebon Medical Corp, Ontario, Canada).
Respiratory effort was assessed by inductance plethysmography
(Respitrace Ambulatory Monitoring, Ardsley, New York, USA), and
arterial oxygen saturation (SaO2) was recorded with a pulse oximeter
(Biox 3740, Ohmeda, Boulder, Colorado, USA). The Remmers
Sleep Recorder is an ambulatory monitor, which measures snoring,
arterial oxygen saturation, respiratory airflow, EKG and body
position. The Remmers Sleep Recorder has been reported to have
excellent agreement, sensitivity and specificity with PSG [23,24].
Measures of exposure
Nocturnal hypoxia. Nocturnal hypoxia was defined as a
SaO2 below 90% for $12% of the total nocturnal monitoring
time. A similar metric of nocturnal hypoxia has been used in the
Sleep Heart Health study [6].
Respiratory Disturbance Index. During PSG, the RDI was
derived from manual scoring of the number of apneas and
hypopneas per hour of sleep. Apnea was defined as a cessation of
airflow for at least 10 s. Hypopnea was defined as an abnormal
respiratory event lasting 10 s or more, with at least a 30%
reduction in thoraco-abdominal movement or airflow compared
with baseline and associated with at least a 4% oxygen desatura-
tion [25]. During nocturnal cardio-pulmonary monitoring, the
RDI was derived from automated analysis of the oximetry signal
using a 4% desaturation threshold [24].
Respiratory Disturbance Index. The RDI is used to assess
the presence and severity of sleep apnea [25]. During PSG, the RDI
was derived from manual scoring of the number of apneas and
hypopneas per hour of sleep. Apnea was defined as a cessation of
airflow for at least 10 s. Hypopnea was defined as an abnormal
respiratory event lasting 10 s or more, with at least a 30% reduction
in thoraco-abdominal movement or airflow compared with baseline
and associated with at least a 4% oxygen desaturation [25]. During
nocturnal cardio-pulmonary monitoring with the Remmers Sleep
Recorder, the RDI was derived from automated analysis of the
oximetry signal using a 4% desaturation threshold. Our sleep centre
has longstanding experience with this monitoring device [23]. It has
been validated by comparison to attended PSG in the sleep
laboratory which showed that the RDI derived by the Remmers
Sleep Recorder was highly correlated with the RDI derived by PSG
(r=0.97) with a sensitivity and specificity of 98% and 88% re-
spectively [24]. More recently, other investigators have validated its
use in the management of patients with obstructive sleep apnea [26].
Obstructive Sleep Apnea (OSA). OSA exposure was defined
as recommended by the American Academy of Sleep Medicine
[25]. Subjects were stratified by OSA severity based on two RDI
cut-points: RDI$15 events/hr and RDI$30 events/hr (severe
OSA).
Measurement of Covariates
Baseline clinical and demographic information was collected for
all participants at the time of sleep diagnostic testing including age,
gender, body mass index (BMI), neck circumference and smok-
ing status. Comorbidity was determined through the use of a
questionnaire administered by trained personnel. Patients were
asked to report the presence of specific comorbidities including
hypertension, myocardial infarction, heart failure, cardiac ar-
rhythmia, stroke, asthma, chronic obstructive pulmonary disease
(COPD), diabetes and depression.
Validated algorithms using administrative data were employed
to define diabetes [27], asthma [28], stroke [29], myocardial
infarction [30], heart failure [31], and hypertension [32]. Using
either self-report or administrative data, an enhanced measure of
comorbidity was developed. This method has been shown to have
face validity and provide clinically meaningful trends in the
prevalence of comorbidity among this population [33].
Ethics
The study was approved by the Conjoint Ethics Review Board
at the University of Calgary. A waiver of consent was granted for
this study, as the individual consent obtained from participants in
the Sleep Cohort study allowed for monitoring use of health care
resources, which included laboratory data.
Statistical Methods
Baseline participant characteristics by presence of nocturnal
hypoxia are presented as the mean 6 standard deviation (SD) for
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dichotomous variables. Differences in baseline characteristics
between categories of nocturnal hypoxia were determined by
chi-squared test or t-test. A mixed-effects model [15] was used to
determine the rate of loss in eGFR in mL/min/1.73 m
2 per year,
with accelerated decline defined as eGFR loss $4 mL/min/
1.73 m
2 per year. The association between nocturnal hypoxia and
accelerated loss of kidney function was assessed using multiple
logistic regression. Initial univariate models were developed to
identify significant predictors of accelerated loss of kidney function.
Using these predictors, saturated multivariate models were
constructed and subsequently reduced by backward elimination
techniques. We removed highly insignificant variables, one at a
time, and compared nested models by using the likelihood ratio
test to determine if there was a significant difference between the
models. The most parsimonious model prior to finding a
significant difference between models was used. Subjects without
nocturnal hypoxia formed the reference group in this analysis.
Similar models were developed to determine the association
between measures of OSA and accelerated loss of kidney function.
OSA was modeled as both a continuous and dichotomous variable.
In the later models, varying RDI cut-points were used to define
OSA severity (RDI$15 events/hr and RDI$30 events/hr).
In all analyses, the assumptions for logistic regression models were
tested and met. All analyses were conducted using SAS (version 9.2,
SAS Institute Inc., Cary, NC) or Stata (version 10.0; Stata Corp,
College Station, TX) with 2-tailed significance levels of 0.05.
Results
During the study period, 2149 participants were referred for
diagnostic testing of sleep apnea. As outlined in Figure 1, 1291
(60%) participants did not meet the inclusion criteria, resulting in a
final study cohort of 858 subjects. Of the 858 participants, 696
(81%) underwent testing using the Remmers Sleep Recorder, and
162 (19%) underwent PSG. In general, participants with nocturnal
hypoxia tended to be older, male, have a greater BMI and neck
circumference and a lower baseline eGFR (Table 1). In addition to
demonstrating a higher prevalence of severe OSA (RDI$30
events/hr), participants with nocturnal hypoxia were also more
likely to have hypertension, diabetes, and a history of cardiovas-
cular disease compared to subjects without nocturnal hypoxia.
Participants with nocturnal hypoxia were also more likely to be
receiving angiotensin converting enzyme-inhibitor (ACE-I) or
angiotensin receptor blockers (ARB) or cardiovascular medications
(including acetylsalicylic acid, nitrates, calcium channel blockers,
arrhythmia medications, and lipid-lowering agents) at the time of
sleep assessment.
Of the 858 participants, 374 (44%) had nocturnal hypoxia and
49 (5.7%) were identified as having accelerated loss of kidney
function. Over a mean (SD) follow-up of 2.1 (0.6) years, the loss of
kidney function was 0.51 ml/min/1.73 m
2/yr greater in partici-
pants with nocturnal hypoxia compared to participants without
nocturnal hypoxia) (p,0.001).
The association between covariates and accelerated loss of
kidney function are outlined in Table 2. As anticipated, age,
presence of hypertension, presence of diabetes, and a history of
cardiovascular disease were each associated with more accelerated
loss of kidney function. Both continuous and categorical measures
of OSA (as defined by RDI) were also independent predictors of
accelerated loss of kidney function. Compared to patients without
nocturnal hypoxia, those with nocturnal hypoxia experienced a
greater than six-fold increase in the unadjusted risk of accelerated
loss of kidney function (Table 3). After adjustment for RDI, age,
body mass index, diabetes and heart failure, the risk was reduced
Figure 1. Formation of study cohort and criteria for exclusion. Abbreviations: eGFR, estimated glomerular filtration rate; SCr, serum creatinine;
TST90, total sleep time spent with oxygen saturation ,90%.
doi:10.1371/journal.pone.0019029.g001
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(OR: 2.89, 95% CI; 2.89, 1.25–6.67). Results were unaffected by
further adjustment for ACE-I/ARB use.
In unadjusted logistic regression, severe OSA (RDI$30 events/
hr) was associated with an increased risk of accelerated loss of
kidney function compared to patients with RDI,30 events/hr
(OR: 4.16, 95% CI; 2.32, 7.49). However, this relationship was no
longer significant after adjustment for age, BMI, diabetes, heart
failure, and nocturnal hypoxia status (OR: 1.68, 95% CI; 0.85,
3.31). Similar results were obtained when RDI$15 events/hr was
used to define disease (OR: 0.71, 95% CI; 0.35, 1.46) or when
RDI was modeled as a continuous variable (OR: 1.01, 95% CI;
1.00, 1.02).
Discussion
Compared to subjects without nocturnal hypoxia, subjects with
nocturnal hypoxia demonstrated an almost three-fold increase in
the risk of accelerated loss of kidney function, even after
adjustment for factors conventionally associated with loss of kid-
ney function such as age, body mass index, diabetes and heart
failure.
While previous studies have addressed the impact of hypoxia on
urinary protein excretion [7,8,9,10,11,12,13], few have examin-
ed the effects of hypoxia on loss of kidney function. A large
retrospective cross-sectional study of patients undergoing PSG for
suspected sleep-disordered breathing demonstrated a significantly
higher prevalence of chronic kidney disease (CKD) compared to
that of age- and sex-matched controls [34], although the impact of
hypoxia on the risk of developing and accelerating CKD was not
addressed. A strong association between nocturnal hypoxia and
risk of hypertension has also been demonstrated in a large cross-
sectional community-based study [6], with subjects experiencing
the greatest duration of sleep with an SaO2 below 90% having
a 46% increased risk of hypertension. In our study the associa-
tion between nocturnal hypoxia and accelerated loss of kidney
function persisted even after adjustment for hypertension and
use of angiotensin-converting enzyme inhibitors and angiotensin
Table 1. Baseline subject characteristics, overall and by presence of nocturnal hypoxia*.
Overall Nocturnal Hypoxia Absent Nocturnal Hypoxia Present p-value
{
n=858 n=484 n=374
Age (years) 55.2 (12.4) 52.8 (12.5) 58.4 (11.6) ,0.001
Males (%) 54.9 51.7 59.1 0.03
Current Smoker (%) 12.4 11.0 14.2 0.2
Baseline eGFR (ml/min/1.73 m
2) 70.8 (12.3) 72.3 (11.3) 68.8 (13.3) ,0.001
Baseline eGFR ,60 ml/min/1.73 m
2 (%) 18.0 13.2 24.1 ,0.001
SaO2,90% (% nocturnal monitoring) 21.8 (27.5) 3.1 (3.27) 46.0 (26.1) ,0.001
RDI 22.9 (25.2) 12.3 (12.0) 36.5 (30.7) ,0.001
RDI$15, % 46.2 26.7 71.4 ,0.001
RDI$30, % 24.6 8.3 45.7 ,0.001
BMI (kg/m
2) 32.8 (7.5) 30.6 (6.7) 35.7 (7.5) ,0.001
Neck Circumference (in)
{ 15.9 (1.9) 15.3 (1.7) 16.7 (1.8) ,0.001
Co-morbidities (%)
Hypertension 55.2 46.5 66.6 ,0.001
Diabetes 19.6 13.6 27.3 ,0.001
Depression 37.3 38.0 36.4 0.6
Asthma 23.7 21.1 27.0 0.04
COPD 7.5 4.6 11.2 ,0.001
Myocardial Infarction 14.6 10.5 19.8 ,0.001
Heart Failure 7.0 3.7 11.2 ,0.001
Stroke 4.6 2.7 7.0 0.003
Medication Use, %
No Medications 13.8 18.2 8.0 ,0.001
ACEI/ARB 32.8 23.4 44.9 ,0.001
Sedative/Hypnotics 11.7 11.4 12.0 0.8
Inhaled Steriods 7.8 5.2 11.2 ,0.001
Cardiovascular Medications 37.9 29.3 48.9 ,0.001
Abbreviations: eGFR, estimated glomerular filtration rate; RDI, respiratory disturbance index; BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACEI,
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Cardiovascular Medications include acetylsalicylic acid, nitrates, calcium channel blockers, beta blockers, arrhythmia medications, and lipid lower medications.
*Results presented as mean (standard deviation) unless otherwise indicated.
{p-value for categorical variables based on a chi-square test of independence; p-value for continuous variables based on a 2-sample t-test for a difference, assuming
equal variances.
{Neck Circumference: n=683 (Overall), n=381 (Nocturnal Hypoxia absent), n=302 (Nocturnal Hypoxia present).
doi:10.1371/journal.pone.0019029.t001
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may be responsible.
There is increasing evidence that hypoxia has a direct effect on
kidney function. Glomerulomegaly and focal segmental glomeru-
losclerosis have both been observed in human renal biopsies in
patients with the sleep apnea syndrome [3,13] and hypoxia is a
common underlying mechanism for CKD progression through
tubulointerstitial injury [1]. In animal studies, intermittent hypoxia
causes a progressive increase in blood pressure, mediated in part
through renal sympathetic nerve activity that acts to increase RAS
activity [35]. In humans, polymorphisms in the angiotensin-
converting enzyme (ACE) gene modulate susceptibility to hyper-
tension in sleep apnea [36], and increased RAS activity is associated
with glomerular hyperfiltration, a precursor to kidney disease.
Nocturnal hypoxia predicts greater glomerular pressure in patients
with chronic obstructive pulmonary disease [4]. and OSA has been
shown to be independently associated with glomerular hyperfiltra-
tion [5]. Furthermore, treatment of OSA with continuous positive
airway pressure resulted in a significant decrease in glomerular
pressure [5], suggesting that reversal of hypoxia may improve
kidney function, though this is clearly speculative. Interestingly, a
negative association between the prevalence of CKD and end-stage
kidney disease and altitude of residence has been shown [37],
indicating that the renal response to hypoxia may differ depending
on whether the exposure is chronic or intermittent.
Our study has many strengths. While previous studies have
shown that sleep apnea is common in adults undergoing
maintenance dialysis [38,39,40], less is known about the potential
impact of sleep apnea and accompanying hypoxia on kidney
function in patients with CKD [41]. To our knowledge, this is the
first study to examine the association between nocturnal hypoxia
and loss of kidney function. Furthermore, we were able to control
for several comorbidities which can also contribute to a decline
in kidney function. The size of the cohort and the fact that all
patients were referred by primary care physicians increase the
generalizability of our findings. Finally, we did not select patients
based on the presence and severity of CKD which reduced the
potential for biased recruitment of those at increased risk of a
decline in kidney function.
Limitations
Our study also has limitations. First, as in all observational
studies, there is the potential for residual confounding. However,
we were able to control for important clinical data that have been
shown to impact loss of kidney function, including hypertension
[27], use of ACE-I or ARBs [14] and use of non-steroidal anti-
inflammatory drugs [28]. We do not have information on alcohol
consumption in our study population. However, alcohol con-
sumption does not appear to impact loss of kidney function
[42,43,44]. Common practice dictates that renal hemodynamic
parameters be indexed to body surface area (BSA) [45], yet it has
been suggested that normalizing to BSA may be inappropriate in
the obese [46,47]. However. as we are measuring loss of kidney
function within subjects rather than between subjects, the accuracy
will be the same for all measurements.
Further, subjects were recruited from patients referred for
diagnostic testing for sleep apnea, which raises the possibility of
referral bias. However, all patients seen at community respiratory
care companies as well as at the FMC Sleep Centre had diagnostic
testing prior to consultation with a sleep physician. Our patient
population was not selected by sleep physicians, but rather by their
primary care physicians who suspected the presence of sleep
apnea. Lastly, although the study is longitudinal the relatively
short duration of follow-up does not exclude reverse causality, i.e.
those with faster decline in kidney function develop nocturnal
hypoxia.
In summary, we found that nocturnal hypoxia was associated
with an increased risk of accelerated loss of kidney function in this
population referred for diagnostic testing of sleep apnea,
suggesting that surveillance of kidney function may be prudent
in patients with sleep disordered breathing. Furthermore, it may
be worthwhile to identify patients with CKD at risk for nocturnal
hypoxia, particularly if their renal function is declining despite
conventional management. Although it remains unclear whether
correction of nocturnal hypoxia improves kidney function, we
believe that this hypothesis merits further study.
Table 2. Univariate analysis for risk of accelerated loss of
kidney function.
Covariate
Risk of Accelerated Loss of
Kidney Function (OR (95% CI)
Male sex 1.44 (0.79, 2.62)
Current Smoker 1.20 (0.52, 2.73)
Age (per year) 1.06 (1.03, 1.09)
Body mass index (per kg/m
2) 1.07 (1.03, 1.10)
Diabetes mellitus 10.30 (5.51, 19.24)
History of congestive heart failure 6.63 (3.34, 13.20)
Hypertension 6.29 (2.65, 14.93)
History of myocardial infarction 2.80 (1.48, 5.32)
History of stroke 2.59 (0.97, 6.95)
ACEI/ARB Use 2.93 (1.63, 5.26)
RDI (events/hr) 1.02 (1.01, 1.03)
OSA ($15 events/hr) 2.09 (1.15, 3.81)
OSA ($30 events/hr) 4.17 (2.32, 7.49)
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; RDI, respiratory disturbance index; OSA, obstructive sleep
apnea.
doi:10.1371/journal.pone.0019029.t002
Table 3. Association between nocturnal hypoxia and risk of accelerated loss of kidney function*.
Unadjusted Model
OR (95% CI)
Multivariate adjusted model{
OR (95% CI)
Multivariate adjusted model
{
OR (95% CI)
Nocturnal hypoxia 6.32 (3.03, 13.20) 3.38 (1.53, 7.45) 2.89 (1.25, 6.67)
Abbreviations: OR, odds ratio; CI, confidence interval.
*Reference group is subjects without nocturnal hypoxia.
{Adjusted for age, body mass index, diabetes and heart failure.
{Adjusted for respiratory disturbance index (RDI), age, body mass index, diabetes and heart failure.
doi:10.1371/journal.pone.0019029.t003
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